Khalil Saleh1, Jean-Marie Michot2, Valérie Camara-Clayette3, Yegor Vassetsky4, Vincent Ribrag5,6. 1. Département d'Hématologie, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94810, Villejuif, France. 2. DITEP, Institut de Cancérologie Gustave Roussy, Villejuif, France. 3. Plateforme AMMICA, Recherche Translationnelle Hématologie, INSERM US23/CNRS UMS3655, Gustave Roussy, Université Paris Sud, Institut de Cancérologie Gustave Roussy, Villejuif, France. 4. Centre National de la Recherche Scientifique (CNRS) UMR 9018, Université Paris Sud, Institut de Cancérologie Gustave Roussy, Villejuif, France. 5. Département d'Hématologie, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94810, Villejuif, France. vincent.ribrag@gustaveroussy.fr. 6. DITEP, Institut de Cancérologie Gustave Roussy, Villejuif, France. vincent.ribrag@gustaveroussy.fr.
Abstract
PURPOSE OF REVIEW: Burkitt's lymphoma and its leukemic form (Burkitt cell acute lymphoblastic leukemia) are a highly aggressive disease. We review the classification, clinical presentation, histology, cytogenetics, and the treatment of the disease. RECENT FINDINGS: Burkitt's lymphoma might be associated with tumor lysis syndrome which is a potentially fatal complication that occurs spontaneously or upon initiation of chemotherapy. Major improvements were made in the treatment of pediatric and adults population using short-course dose-intensive chemotherapy regimens, usually 1 week after a prephase induction. Addition of Rituximab to chemotherapy has become a standard of care. Relapsed/refractory disease has a very poor prognosis and the benefit from autologous/allogeneic hematopoietic stem cell transplant remains uncertain. Rituximab-based short-course dose-intensive chemotherapy is the standard of care of Burkitt's lymphoma even in the immunodeficiency-related form.
PURPOSE OF REVIEW: Burkitt's lymphoma and its leukemic form (Burkitt cell acute lymphoblastic leukemia) are a highly aggressive disease. We review the classification, clinical presentation, histology, cytogenetics, and the treatment of the disease. RECENT FINDINGS:Burkitt's lymphoma might be associated with tumor lysis syndrome which is a potentially fatal complication that occurs spontaneously or upon initiation of chemotherapy. Major improvements were made in the treatment of pediatric and adults population using short-course dose-intensive chemotherapy regimens, usually 1 week after a prephase induction. Addition of Rituximab to chemotherapy has become a standard of care. Relapsed/refractory disease has a very poor prognosis and the benefit from autologous/allogeneic hematopoietic stem cell transplant remains uncertain. Rituximab-based short-course dose-intensive chemotherapy is the standard of care of Burkitt's lymphoma even in the immunodeficiency-related form.
Authors: Kevin W Song; Michael J Barnett; Randy D Gascoyne; Douglas E Horsman; Donna L Forrest; Donna E Hogge; Julyle C Lavoie; Stephen H Nantel; Thomas J Nevill; John D Shepherd; Clayton A Smith; Heather J Sutherland; Nicholas J Voss; Cynthia L Toze; Joseph M Connors Journal: Br J Haematol Date: 2006-06 Impact factor: 6.998
Authors: Stanton Goldman; Lynette Smith; Paul Galardy; Sherrie L Perkins; John Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Bruce Shiramizu; Matthew Barth; Mitchell S Cairo Journal: Br J Haematol Date: 2014-07-26 Impact factor: 6.998
Authors: Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis J Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Hagop Kantarjian Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: M Spina; U Tirelli; V Zagonel; A Gloghini; R Volpe; R Babare; L Abbruzzese; R Talamini; E Vaccher; A Carbone Journal: Cancer Date: 1998-02-15 Impact factor: 6.860
Authors: C Patte; T Philip; C Rodary; J M Zucker; H Behrendt; J C Gentet; J P Lamagnère; J Otten; D Dufillot; F Pein Journal: J Clin Oncol Date: 1991-01 Impact factor: 44.544
Authors: A Reiter; M Schrappe; R Parwaresch; G Henze; S Müller-Weihrich; S Sauter; K W Sykora; W D Ludwig; H Gadner; H Riehm Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: S B Murphy; W P Bowman; M Abromowitch; J Mirro; J Ochs; G Rivera; C H Pui; D Fairclough; C W Berard Journal: J Clin Oncol Date: 1986-12 Impact factor: 44.544